Digital Vision Screening Platform Aims to Decrease Vision Loss Rates for Patients With Eye Disorders
May 24, 2022 11:00 ET
|
Retina Technologies, Inc
NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- Retina Technologies, Inc. ("RetTech") is advancing the development of OcuVue™, an affordable, digital vision screening platform with integrated...
Amydis Announces Successful Completion of a Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALS
December 06, 2021 07:00 ET
|
Amydis, Inc.
SAN DIEGO, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a biotechnology company developing novel ocular contrast agents (“tracers”) targeting CNS biomarkers in the eye, today announced the...
Global Nonmydriatic Handheld Fundus Cameras Market Report 2021: Market to Reach $192.6 Million by 2026 - Fundus Camera Sales Hit by the Pandemic, Poised for Strong Revival
December 06, 2021 05:38 ET
|
Research and Markets
Dublin, Dec. 06, 2021 (GLOBE NEWSWIRE) -- The "Nonmydriatic Handheld Fundus Cameras - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global...
Global $525+ Million Ophthalmology Optical Coherence Tomography (OCT) Markets Analysis & Forecasts, 2016-2020 & 2021-2026
November 18, 2021 06:33 ET
|
Research and Markets
Dublin, Nov. 18, 2021 (GLOBE NEWSWIRE) -- The "Optical Coherence Tomography (OCT) for Ophthalmology - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's...
Amydis Awarded $3 Million NIH Grant to Explore Novel Alpha Synuclein Retinal Tracer in Non-human Primate Models of Parkinson’s Disease and Multiple System Atrophy
October 11, 2021 07:00 ET
|
Amydis, Inc.
SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...
Amydis Receives NIH Grant Award to Develop a Novel Tau Retinal Tracer for Alzheimer's Diseases and other Tauopathies
September 02, 2021 07:00 ET
|
Amydis, Inc.
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...
Amydis Receives $3 Million NIH Commercialization Readiness Pilot Grant Award for Novel Amyloid Beta Retinal Tracer in Cerebral Amyloid Angiopathy
June 28, 2021 07:00 ET
|
Amydis, Inc.
SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...
Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer for the Diagnosis of Alpha-synucleinopathies
April 26, 2021 07:00 ET
|
Amydis, Inc.
SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer biotechnology company with a broad portfolio of diagnostic candidates for detection of neurodegenerative diseases...
Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of AMDX-2011P, a First-in-Class Retinal Tracer for the Diagnosis of Amyloid Angiopathy
January 11, 2021 07:00 ET
|
Amydis, Inc.
SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...
Amydis Awarded Michael J. Fox Foundation Grant to Accelerate Development of an Alpha-Synuclein Retinal Tracer to Diagnose Parkinson’s Disease Through the Eye
August 11, 2020 07:00 ET
|
Amydis, Inc.
SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Amydis, Inc., a biotechnology company developing a new class of diagnostics to enable the early detection of neurological diseases through the retina,...